公开(公告)号：US20180243275A1

公开(公告)日：2018-08-30

申请号：US15754244

申请日：2016-08-26

Applicant: The Texas A&M University System

Inventor： Manchi CM Reddy ,  James C. Sacchettini ,  Spandana Valluru

IPC: A61K31/44 ,  A61K31/498 ,  A61K31/423 ,  A61K31/428 ,  A61K31/501 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/7036 ,  A61P33/02

CPC classification number: A61K31/44 ,  A61K31/353 ,  A61K31/423 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/7036 ,  A61P33/02 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/419 ,  Y02A50/421 ,  Y02A50/423 ,  Y02A50/49 ,  Y02A50/491

Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphen-oxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.

公开(公告)号：US20180111913A1

公开(公告)日：2018-04-26

申请号：US15568268

申请日：2016-04-22

Applicant: The Texas A&M University System

Inventor： James C. Sacchettini ,  Anup Aggarwal ,  Maloy K. Parai

IPC: C07D307/84 ,  C07D405/04 ,  C07D235/18 ,  C07D405/06 ,  A61K31/4525 ,  A61K31/4025 ,  A61K31/55 ,  A61K31/5377 ,  A61K31/343 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4545 ,  A61K45/06 ,  A61P31/00 ,  A61P31/06

CPC classification number: C07D307/84 ,  A61K31/343 ,  A61K31/4025 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P31/00 ,  A61P31/06 ,  C07D235/18 ,  C07D307/80 ,  C07D307/81 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06

Abstract: Novel bacterial inhibitors comprising benzofuran derivatives, and methods of bacterial inhibition using the inhibitors are disclosed. The inhibitors may inhibit, for example, mycobacteria, including M. tuberculosis, by inhibition of the Pks13 enzyme. The inhibitors cmat exhibit potent whole cell and in vivo efficacy against M. tuberculosis.